Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Sanford Broadway Medical Center
mi
from
Fargo, ND
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Sanford Broadway Medical Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital-Cedar Crest
mi
from
Allentown, PA
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital-Cedar Crest
mi
from
Allentown, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Penn State Children's Hospital
mi
from
Hershey, PA
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Penn State Children's Hospital
mi
from
Hershey, PA
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
The Children's Hospital at TriStar Centennial
mi
from
Nashville, TN
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
The Children's Hospital at TriStar Centennial
mi
from
Nashville, TN
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Texas Tech University Health Sciences Center at Amarillo
mi
from
Amarillo, TX
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Texas Tech University Health Sciences Center at Amarillo
mi
from
Amarillo, TX
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
University Medical Center
mi
from
Lubbock, TX
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
University Medical Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of San Antonio
mi
from
San Antonio, TX
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
West Virginia University Charleston Division
mi
from
Charleston, WV
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
West Virginia University Charleston Division
mi
from
Charleston, WV
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
University of California Medical Center, San Francisco
mi
from
San Francisco, CA
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
University of California Medical Center, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
University of Illinois Medical Center, Chicago
mi
from
Chicago, IL
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
University of Illinois Medical Center, Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Evanston NW Healthcare
mi
from
Evanston, IL
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Evanston NW Healthcare
mi
from
Evanston, IL
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated:  12/31/1969
Institute of Cancer Epidemiology
mi
from
Copenhagen,
Gliogene: Brain Tumor Linkage Study
Gliogene: Brain Tumor Linkage Study
Status: Enrolling
Updated: 12/31/1969
Institute of Cancer Epidemiology
mi
from
Copenhagen,
Click here to add this to my saved trials
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
Genetic Basis of Neuroblastoma Tumorigenesis
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
Genetic Basis of Neuroblastoma Tumorigenesis
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
Genetic Basis of Neuroblastoma Tumorigenesis
Status: Enrolling
Updated:  12/31/1969
Children's Oncology Group
mi
from
Philadelphia, PA
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
Genetic Basis of Neuroblastoma Tumorigenesis
Status: Enrolling
Updated: 12/31/1969
Children's Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber/Brigham and Women's Cancer Center
mi
from
Boston, MA
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber/Brigham and Women's Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase I/II Study of ZD6474 (Vandetanib) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
A Phase I Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
A Phase I Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Hawaii Pacific Health
mi
from
Lihue, HI
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Hawaii Pacific Health
mi
from
Lihue, HI
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Steven and Alexandra Cohen Children's Medical Center of New York- North Shore LIJ
mi
from
New Hyde Park, NY
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Steven and Alexandra Cohen Children's Medical Center of New York- North Shore LIJ
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
NYU Hassenfeld Center
mi
from
New York, NY
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
NYU Hassenfeld Center
mi
from
New York, NY
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Medical Center of Dallas
mi
from
Dallas, TX
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Medical Center of Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center (MDACC)
mi
from
Houston, TX
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center (MDACC)
mi
from
Houston, TX
Click here to add this to my saved trials